# US 2024/0200056 A1 · Multiplex genome engineering in eukaryotes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0200056 A1
- Document ID: US20240200056A1
- Status: Published application
- Kind: A1
- Application number: 18/340,687
- Filed: 2023-06-23
- Published: 2024-06-20
- Earliest claimed: 2016-04-27
- Assignees: Yale University
- Applicants: Yale University
- Inventors: Edward Barbieri; Farren Isaacs
- Web page: https://patentgrep.com/patent/US20240200056A1

## CPC

- C12N 15/1058: {Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms}
- C12N 15/1079: {Screening libraries by altering the phenotype or phenotypic trait of the host (reporter assays C12N15/1086)}
- C12N 15/1082: {Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors}
- C12N 15/1086: {Preparation or screening of expression libraries, e.g. reporter assays}
- C40B 30/06: by measuring effects on living organisms, tissues or cells
- C40B 40/02: Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
- G01N 33/5014: {for testing toxicity}
- C12N 15/102: {Mutagenizing nucleic acids}
- C12Q 2525/185: incorporating bases where the precise position of the bases in the nucleic acid string is important
- C12Q 2543/10: the purpose being "in situ" analysis
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Compositions and methods for gene editing are provided. The methods employ an oligo-based annealing mechanism that is rooted in the process of DNA replication rather than homologous recombination (HR). Oligo incorporation efficiencies are comparable and often exceed those of CRISPR/cas9 editing without the need for double strand breaks (DSBs). By relying on the multiplex annealing of oligos rather than DSBs the process is highly scalable across a genomic region of interest and can generate many scarless modifications of a chromosome simultaneously. Combinatorial genomic diversity can be generated across a population of cells in a single transformation event; genomic landscapes can be traversed through successive iterations of the process, and genome-wide changes can be massively parallelized and amplified through systematic strain mating.

## Claims

### Claim 1

A method for preparing a library of mutant eukaryotic cells comprising:
(i) transfecting or transforming a population of eukaryotic host cells with (a) an oligonucleotide that can introduce one or more mutations into a selectable marker when incorporated into a cell's genome by replication fork annealing and (b) one or more oligonucleotides that can introduce one or more mutations into a target region when incorporated into a cell's genome by replication fork annealing; and
(ii) selecting mutant cells that have a mutation in the selectable marker.

### Claim 2 (depends on 1)

The method of claim 1, wherein the target region and the selectable marker are separated by 2, 1, or 0 origins of replication.

### Claim 3 (depends on 1)

The method of claim 1, wherein the target regions have a length from between 1 base pair to 2 million base pairs, up to 100 million base pairs from the origin of replication closest to the selectable marker.

### Claim 4 (depends on 1)

The method of claim 1, wherein the selectable marker is a counter-selectable marker and mutant cells are selected by culturing the transfected cells in presences of a compound that kills cells expressing the un-mutated selectable marker.

### Claim 5 (depends on 1)

The method of claim 1, wherein the one or more oligonucleotides of step (b) introduce mutations into a gene regulatory region, an open reading frame, an intron, or a combination thereof.

### Claim 6 (depends on 5)

The method of claim 5, wherein the mutations are insertions, deletions, substitutions, or a combination thereof.

### Claim 7 (depends on 1)

The method of claim 1, wherein the oligonucleotides of (a) and (b) are each about 30 and 120 nucleotides in length.

### Claim 8 (depends on 1)

The method of claim 1, wherein the oligonucleotides of (b) are a pool of oligonucleotides each comprising 1 or more mutations.

### Claim 9 (depends on 1)

The method of claim 1, further comprising (iii) selecting mutant cells that have a mutation in the target region.

### Claim 10 (depends on 9)

The method of claim 9, wherein the selection of mutant cells with a mutation in the target region comprises phenotypic or genotypic screening.

### Claim 11 (depends on 1)

The method of claim 1, wherein the host cells are selected from the group consisting of animal cells, ciliate cells, plant cells, fungi, yeasts, flagellates, microsporidia, and protozoa

### Claim 12 (depends on 1)

The method of claim 1, wherein the host cells are deleted or otherwise treated or altered to reduce the expression of the RAD51 gene, or to otherwise reduce or inhibit the RAD51 gene product or a homolog thereof, alone or in combination with RAD52.

### Claim 13 (depends on 1)

The method of claim 1, wherein the host cells are deleted or otherwise treated or altered to reduce expression of one or more DNA mismatch repair enzymes.

### Claim 14 (depends on 13)

The method of claim 13, wherein the DNA mismatch repair enzyme is selected from the group consisting of MSH2, MSH6, MLH1, PMS1, homologs there, and combinations thereof.

### Claim 15 (depends on 1)

The method of claim 1, wherein expression of RAD59 or another ssDNA annealing or binding protein or recombinase is increased in the host cells.

### Claim 16 (depends on 1)

The method of claim 1, wherein the host cells are treated prior to and/or during step (i) to reduce replication fork speed.

### Claim 17

(canceled)

### Claim 18 (depends on 1)

The method of claim 1, wherein steps (i) and (ii) are repeated for two or more cycles using the same or different oligonucleotides for steps (a) and (b).

### Claim 19

(canceled)

### Claim 20 (depends on 1)

A library of mutant cells prepared according to the method of claim 1.

### Claim 21 (depends on 20)

A single cell or clonal colony there of isolated from the library of claim 20.

### Claim 22

A genetically modified or transfected eukaryotic cell comprising a selectable marker adjacent to an origin of replication.

### Claim at position 23

-30. (canceled)
